Glucophage Sr

Basic Glucophage Sr Information

• INN (International Nonproprietary Name): Metformin hydrochloride (Metforminum hydrochloridum)
• Brand Names Available In United Kingdom: Glucophage SR (internationally listed); similar extended‑release products available in the EU include Metformin STADA SR and Metformin Teva SR; UK pharmacies commonly dispense generic metformin SR or equivalent branded ER products.
• ATC Code: A10BA02 (Metformin; biguanides — blood glucose lowering drugs, excluding insulins)
• Forms & Dosages: Extended‑release tablets in 500 mg, 750 mg and 1000 mg strengths; designed for oral, once‑daily administration.
• Manufacturers In United Kingdom: Not specified; manufacturers supplying SR products in the EU include Sanofi, Teva, STADA, Zentiva and Medochemie; global suppliers include Bristol‑Myers Squibb (historically), Sun Pharma, Torrent and Cipla.
• Registration Status In United Kingdom: Not specified for a UK licence in the raw data; product class is generally registered in the EU/EMA framework and local registrations vary by member state.
• OTC / Rx Classification: Prescription Medicine (Rx/POM) in major markets and therefore supplied on NHS or private prescription in the UK.

Critical Warnings & Restrictions (Safety First — UK Focus)

People ask first: “Who should not take Glucophage SR?”

Glucophage SR contains metformin hydrochloride (INN: metformin hydrochloride) and is a Prescription Only Medicine (POM).

Do not start or continue Glucophage SR if your estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m²; review treatment if eGFR is between 30–45 mL/min/1.73 m² and do not initiate in that range.

Avoid Glucophage SR in acute or chronic metabolic acidosis (including diabetic ketoacidosis), recent tissue hypoxia such as severe cardiac or respiratory failure, or if there is significant alcoholism; these are absolute contraindications.

High‑Risk Groups

Elderly patients require caution; establish renal function before prescribing and monitor renal function frequently thereafter.

Pregnancy and breastfeeding require discussion with a clinician; use alternatives when appropriate and follow specialist advice.

Hepatic impairment increases the risk of lactic acidosis and Glucophage SR should be avoided where possible in significant liver disease.

Absolute Versus Relative Contraindications

• Absolute Contraindications: eGFR <30 mL/min/1.73 m²; known hypersensitivity to metformin or excipients; acute or chronic metabolic acidosis including diabetic ketoacidosis; recent or ongoing tissue hypoxia (severe cardiac/respiratory failure, shock); alcoholism.
• Relative Contraindications / Cautions: eGFR 30–45 mL/min/1.73 m² (do not initiate); age over 80 years unless normal renal function is established; lactation; conditions predisposing to renal dysfunction (dehydration, significant infection, iodinated contrast exposure).

Baseline Tests Checklist

• Measure eGFR before starting treatment and document result.
• Perform baseline liver function tests (LFTs) and review hepatic history.
• Record baseline vitamin B12 status when clinically indicated, especially if long‑term therapy planned.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

If you experience gastrointestinal side effects that cause dizziness or lightheadedness, exercise caution when driving or operating machinery.

Follow DVLA guidance where medications or diabetes itself affect alertness or cause hypoglycaemia risk; discuss any concerns with your clinician.

Q&A — Can I Drive After Taking It In The UK?

Short answer: Usually yes, provided you have no symptoms that affect alertness.

Stop driving and seek medical advice if you experience severe dizziness, fainting, confusion or suspected hypoglycaemia.

Report changes in your condition to your clinician and, where required, inform the DVLA.

Usage Basics

INN, Brand Names Available In The UK

The INN is metformin hydrochloride (Metforminum hydrochloridum).

Extended‑release products are commonly referenced as Glucophage SR or Glucophage XR internationally.

In the EU there are SR products listed as Glucophage SR, Metformin STADA SR and Metformin Teva SR, and UK pharmacies typically dispense generics or equivalent branded ER tablets.

• Common strengths dispensed: 500 mg, 750 mg and 1000 mg SR tablets.
• Formulation: sustained/extended‑release tablets for once‑daily oral use.

Legal Classification (POM, P, GSL)

Glucophage SR and other metformin SR products are classified as prescription medicines (POM/Rx) across major markets.

In the UK Glucophage SR is supplied on an NHS prescription or a private prescription.

Definitions:

• POM (Prescription Only Medicine): Medicine supplied only with a prescription from an authorised prescriber.
• P (Pharmacy Medicine): Sold under pharmacist supervision without a prescription — not applicable to Glucophage SR.
• GSL (General Sales List): Sold without pharmacist supervision — not applicable to Glucophage SR.

Dosing Guide

Standard Regimens (NHS Guidelines)

Patients often ask: “How do I start Glucophage SR safely?”

Typical adult initiation for type 2 diabetes is 500 mg once daily with the evening meal, increasing by 500 mg weekly as tolerated.

The usual target dose is around 2000 mg per day although some product licences support up to 2500 mg/day; always follow the product licence and local NHS guidance.

SR formulations are designed for once‑daily dosing to improve adherence and to reduce peak gastrointestinal effects compared with immediate‑release forms.

Adjustments For Comorbidities

Do not start metformin if eGFR is between 30–45 mL/min/1.73 m²; assess risk versus benefit and review regularly.

Stop metformin if eGFR falls below 30 mL/min/1.73 m².

Elderly patients should have a lower starting dose and closer renal monitoring.

Avoid or adjust metformin during acute illness, dehydration or before contrast imaging; follow local protocols for suspension and re‑checking renal function.

Q&A — What If I Miss A Dose?

Take the missed dose as soon as you remember unless it is almost time for your next dose.

Do not double up to make up a missed dose.

If you are unsure, contact your pharmacist or diabetes team for personalised advice.

Checklist for titration and monitoring:

• Start 500 mg once daily with the evening meal.
• Increase by 500 mg weekly as tolerated until an effective dose is reached.
• Baseline eGFR before starting, repeat at 3 months, then at least annually or more often if clinically indicated.
• Check HbA1c per NHS diabetes review schedules and monitor vitamin B12 in long‑term users.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Alcohol increases the risk of lactic acidosis and should be limited; binge drinking is a contraindication.

There are no major food interactions with Glucophage SR, but taking the SR tablet with the evening meal reduces gastrointestinal upset.

Caffeine can alter short‑term glycaemic variability; advise patients to keep intake consistent day to day.

Common Drug Conflicts (MHRA Yellow Card Data)

Certain medicines may increase metformin levels or affect renal function and so require caution or dose review.

Examples include iodinated contrast agents (suspend metformin per local imaging protocols), nephrotoxic drugs such as NSAIDs or scenarios of ACE inhibitor use in dehydration, and drugs like cimetidine which can reduce metformin clearance.

Immediate actions on suspicion of interaction:

• Stop metformin if acute renal impairment is suspected.
• Check eGFR and review concurrent medications.
• Report suspected adverse interactions to the MHRA Yellow Card scheme.

User Reports & Trends

Patients commonly report transient gastrointestinal upset such as nausea and diarrhoea when starting metformin SR.

Many appreciate the convenience of once‑daily SR dosing and report better adherence compared with multiple daily doses.

Weight tends to stabilise or show modest reduction on metformin; experiences vary and depend on lifestyle changes too.

• Top patient themes: gastrointestinal effects, dosing convenience, cost concerns and monitoring queries.
• SR formulations often score higher for tolerability and adherence in patient forums.
• Patients increasingly ask about brand versus generic, cost and availability of 500/750/1000 mg SR strengths.

Suggested clinician checklist for follow‑up: ask about GI symptoms, check adherence, review alcohol intake, and re‑assess renal function.

Access & Purchase Options (UK)

High‑Street Pharmacies (Boots, LloydsPharmacy, Superdrug)

Glucophage SR or equivalent metformin SR products are dispensed on prescription at major pharmacy chains and independent pharmacies across the UK.

Pharmacists provide counselling, check interactions and can review renal safety at the point of supply.

Private prescriptions are an option when immediate supply is required.

Online Pharmacies And NHS E‑Prescriptions

Electronic prescribing and NHS e‑prescriptions allow direct collection or home delivery from registered UK pharmacies.

Only use pharmacies registered with the General Pharmaceutical Council (GPhC) and MHRA‑registered suppliers.

Checklist for safe purchase:

• Use a registered UK pharmacy and ensure a valid NHS or private prescription.
• Confirm product licence and batch packaging when buying privately.
• Avoid unregulated overseas suppliers and check pharmacist counselling is available.

In our online pharmacy, glucophage sr is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Mechanism & Pharmacology

Simplified Explanation

Metformin lowers blood glucose mainly by reducing hepatic gluconeogenesis and by improving peripheral insulin sensitivity.

It also has modest effects on intestinal glucose absorption which contribute to its glucose‑lowering action.

Sustained/extended‑release (SR/ER) formulations smooth plasma concentrations over 24 hours and reduce peak concentrations, which helps improve gastrointestinal tolerability and supports once‑daily dosing.

Clinical Terms

• Gluconeogenesis: The liver’s production of glucose from non‑carbohydrate sources.
• eGFR: Estimated glomerular filtration rate, a measure of kidney function used to guide dosing and safety.
• SR/ER: Sustained Release / Extended Release, formulations designed for slower drug release to maintain steadier blood levels.
• ATC Code A10BA02: Classification showing metformin is a biguanide within blood glucose lowering drugs excluding insulin.

For clinical pages, a simple diagram might read: Metformin → Reduced Hepatic Glucose Production + Improved Insulin Sensitivity → Lower Fasting Glucose and HbA1c.

Indications & Off‑Label Uses

MHRA‑Approved Uses

Primary licensed indication is for glycaemic control in adults with type 2 diabetes as part of diet and lifestyle measures.

SR formulations are approved in various strengths for once‑daily use.

SR forms are not generally indicated for children or adolescents under 18 years due to limited data for that age group.

Off‑Label Practices In NHS And Private Care

Off‑label uses include treatment for polycystic ovary syndrome (PCOS) where insulin resistance is implicated and for certain weight‑metabolic investigations in specialist settings.

• Licensed: Type 2 diabetes in adults.
• Commonly Off‑Label: Insulin resistance in PCOS and selected metabolic research uses.

When prescribing off‑label, clinicians should document rationale and obtain informed discussion and consent.

Key Clinical Findings (UK & EU Focus)

Metformin is supported by guideline bodies as a first‑line agent in type 2 diabetes and SR formulations improve adherence and gastrointestinal tolerability.

Selected UK and EU analyses continue to show cardiovascular neutrality or benefit when metformin is used early alongside risk factor control.

Long‑term metformin use is associated with a risk of vitamin B12 deficiency and periodic monitoring is advised.

• What the evidence means for practice: use as first‑line therapy where appropriate, monitor renal function and B12, and consider SR for patients needing once‑daily dosing to improve adherence.
• SR formulations can be preferred where GI side effects limit continuation of immediate‑release metformin.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Consider comorbidities such as cardiorenal disease when choosing alternatives.
• Assess renal function and hypoglycaemia risk for each option.
• Discuss weight goals, pregnancy plans and cost with the patient before switching or adding therapies.

Common Questions

Q: Will Glucophage SR Make Me Gain Weight?

A: Metformin is generally weight‑neutral or associated with modest weight reduction; sulfonylureas and insulin are more commonly linked to weight gain.

Q: Should I Have Regular Blood Tests?

A: Yes — baseline and regular eGFR checks, periodic vitamin B12 checks for long‑term users, and HbA1c according to NHS diabetes review schedules.

Q: Can Pregnant Women Take It?

A: Pregnancy requires specialist input; many clinicians use insulin for tight glycaemic control, though metformin may be used in some circumstances after discussion with the obstetric team.

Seek Urgent Help Checklist:

• Severe unexplained tiredness, muscle pain or breathlessness — possible lactic acidosis.
• Marked decline in urine output or rapid rise in creatinine/eGFR fall.
• Severe gastrointestinal upset or persistent vomiting.

NHS Cost & Access Comparison Table

Regional prescription policies differ across the UK.

England uses NHS prescription charges unless the patient is exempt; Scotland, Wales and Northern Ireland currently provide free NHS prescriptions to residents.

Regional Differences Table:

For up‑to‑date charges and local formulary options, link to NHS resources or consult your local pharmacy.

Registration & Regulation

MHRA Approval Process

The MHRA evaluates product licences for safety, efficacy and quality, and local product names or licences may vary.

All suspected adverse reactions should be reported via the MHRA Yellow Card scheme for pharmacovigilance.

NHS Prescribing Framework

Follow local formularies and NHS England guidance for diabetes management when prescribing metformin SR.

• Prescriber checks before initiation: eGFR, hepatic history, pregnancy status and concurrent medications.
• Use Yellow Card for reporting and follow local clinical governance for documentation.

Storage & Handling

UK Household Storage (Cold/Damp Climate)

Store Glucophage SR at room temperature, ideally between 15–30°C, in a dry place away from direct heat and moisture.

Keep the medicine in its original packaging and out of the reach of children.

Do not refrigerate.

Guidance From NHS And Pharmacists

Dispose of unused medicine at pharmacy return points; do not flush medicines down the toilet or sink.

Pharmacists can advise if a dose has been exposed to temperature extremes and whether it remains suitable for use.

Guidelines For Proper Use (Pharmacist Counselling & NHS Patient Safety)

UK Pharmacist Counselling Style

Key counselling points to cover at supply: take Glucophage SR with the evening meal to reduce gastrointestinal side effects.

Explain the titration schedule and reinforce not to double doses.

Advise patients to inform clinicians about alcohol intake, intercurrent illness and to stop metformin before major radiological contrast per local protocol and re‑check renal function before restarting.

NHS Patient Safety Advice

Monitor baseline and periodic eGFR, HbA1c and vitamin B12 as appropriate.

Instruct patients to recognise signs of lactic acidosis such as unusual fatigue, muscle pain, abdominal pain or fast breathing, and to seek urgent care if these occur.

Provide written information and check patient understanding at the dispensary.

• Follow‑up appointment checklist: review adherence, record eGFR and HbA1c, ask about GI side effects and alcohol use.
• Patient medication record card: list dose, date started, prescriber contact and emergency advice.

Delivery Across United Kingdom